William Maughan
Stock Analyst at Canaccord Genuity
(2.96)
# 1,243
Out of 4,829 analysts
24
Total ratings
54.17%
Success rate
55.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $171 → $171 | $97.27 | +76.25% | 13 | Nov 27, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $20 → $18 | $4.07 | +342.26% | 2 | Mar 31, 2023 | |
| XNCR Xencor | Maintains: Buy | $48 → $42 | $8.77 | +378.91% | 6 | Feb 24, 2023 | |
| OLMA Olema Pharmaceuticals | Assumes: Buy | $16 | $4.76 | +236.13% | 2 | Jul 6, 2022 | |
| BCYC Bicycle Therapeutics | Assumes: Buy | $60 | $8.60 | +597.67% | 1 | Jul 6, 2022 |
BioNTech SE
Nov 27, 2024
Maintains: Buy
Price Target: $171 → $171
Current: $97.27
Upside: +76.25%
Y-mAbs Therapeutics
Mar 31, 2023
Maintains: Buy
Price Target: $20 → $18
Current: $4.07
Upside: +342.26%
Xencor
Feb 24, 2023
Maintains: Buy
Price Target: $48 → $42
Current: $8.77
Upside: +378.91%
Olema Pharmaceuticals
Jul 6, 2022
Assumes: Buy
Price Target: $16
Current: $4.76
Upside: +236.13%
Bicycle Therapeutics
Jul 6, 2022
Assumes: Buy
Price Target: $60
Current: $8.60
Upside: +597.67%